Nanopharmaceuticals LLC
Records under this name other than the patents Nanopharmaceuticals LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Back to Nanopharmaceuticals LLC
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,859,539 | Compositions of Dual Thyrointegrin Antagonists and Use in Vascular-Associated Disorders Lapsed on the fee record Ended Oct 14, 2026 · High confidence | Lapsed on the fee record | Ended Oct 14, 2026 | High confidence |
| US 10,060,934 | Methods for Screening Patients for Resistance to Angioinhibition, Treatment and Prophylaxis Thereof Lapsed on the fee record Ended Aug 28, 2026 · High confidence | Lapsed on the fee record | Ended Aug 28, 2026 | High confidence |
| US 8,802,240 | Uses of Formulations of Thyroid Hormone Analogs and Nanoparticulate Forms Thereof to Increase Chemosensivity and Radiosensitivity in Tumor or Cancer Cells Lapsed on the fee record Ended Aug 12, 2026 · High confidence | Lapsed on the fee record | Ended Aug 12, 2026 | High confidence |
| US 8,668,926 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof Lapsed on the fee record Ended Mar 11, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 11, 2026 | USPTO record |
| US 9,839,614 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof Lapsed on the fee record Ended Dec 12, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 12, 2025 | USPTO record |
| US 8,518,451 | Thyroid hormone analogs and methods of use Lapsed on the fee record Ended Aug 27, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 27, 2025 | USPTO record |
| US 9,750,709 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof Term ended Term ended Jul 17, 2025 · USPTO record | Term ended | Term ended Jul 17, 2025 | USPTO record |
| US 9,579,300 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof Term ended Term ended Nov 18, 2024 · USPTO record | Term ended | Term ended Nov 18, 2024 | USPTO record |
| US 9,498,536 | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders Term ended Ended no later than Sep 15, 2024 · USPTO record | Term ended | Ended no later than Sep 15, 2024 | USPTO record |
| US 10,130,686 | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders Term ended Ended no later than Sep 15, 2024 · USPTO record | Term ended | Ended no later than Sep 15, 2024 | USPTO record |